Cambridge Investment Research Advisors’s Taysha Gene Therapies TSHA Stock Holding History

Cambridge Investment Research Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$103K	Sell	15,075 -7,305	-33%	-$43.2K	﹤0.01%	3928
2026 Q1	$100K	Buy	22,380 +300	+1%	+$1.4K	﹤0.01%	3793
2025 Q4	$121K	Sell	22,080 -1,610	-7%	-$7.82K	﹤0.01%	3679
2025 Q3	$77K	Hold	23,690	–	–	﹤0.01%	3617
2025 Q2	$55K	Buy	23,690 +200	+0.9%	+$435	﹤0.01%	3535
2025 Q1	$33K	Hold	23,490	–	–	﹤0.01%	3431
2024 Q4	$41K	Sell	23,490 -15	-0.1%	-$31	﹤0.01%	3390
2024 Q3	$47K	Buy	23,505 +7,000	+42%	+$15.4K	﹤0.01%	3336
2024 Q2	$37K	Sell	16,505 -785	-5%	-$2.28K	﹤0.01%	3241
2024 Q1	$50K	Buy	+17,290	New	+$36K	﹤0.01%	3215

Other funds holding TSHA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Cambridge Investment Research Advisors's TSHA Position: Q2 2026 in Review

Cambridge Investment Research Advisors reduced its Taysha Gene Therapies (TSHA) stake by 33% in Q2 2026, selling an estimated $43.2K and leaving 15,075 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #3928.

Cambridge Investment Research Advisors first reported a position in TSHA in Q1 2024 and has held it in 10 quarters since. The position peaked at $121K in Q4 2025. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Cambridge Investment Research Advisors held 15,075 shares of Taysha Gene Therapies worth $103K as of Q2 2026.
Cambridge Investment Research Advisors sold 7,305 Taysha Gene Therapies shares in Q2 2026, an estimated $43.2K.
Taysha Gene Therapies made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3928 holding.
Cambridge Investment Research Advisors first reported a position in Taysha Gene Therapies in Q1 2024 and has held it in 10 quarters since.
Cambridge Investment Research Advisors's Taysha Gene Therapies position peaked at $121K in Q4 2025.
208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.